~ Company Plans to Gain Access to the #7 Level (Sangria) Adit ~

VANCOUVER, BC / ACCESSWIRE / June 24, 2020 / VanGold Mining Corp. (the "Company" or "VanGold") (TSXV:VGLD) announces plans to begin clearing the El Pinguico shaft at its El Pinguico silver and gold project, located 7km south of the city of Guanajuato, Mexico.

Clearing the El Pinguico Shaft:

Preparations are underway to begin clearing approximately 30m of debris from the bottom of the El Pinguico shaft, one of three shafts that gave access to the historic El Pinguico mine.

The company will be attaching a one tonne capacity hoist to its previously installed steel head-frame in order to hoist material that has fallen to the bottom of the El Pinguico shaft since mining ceased in 1913. The company has begun hiring a team of experienced underground miners to perform the delicate work of removing this material safely while maintaining the structural integrity of the shaft. All activities will be performed according to Mexican regulations regarding the prevention of the spread of COVID-19.

The Company plans to begin this operation in mid-July, and has started the process of hiring key personnel for this task. It anticipates that once crews begin this work that it will require approximately three weeks to clear the shaft down to the #7, or ‘Sangria' adit level.

Permitting:

All necessary permits to operate the one tonne capacity hoist, and remove the material from the bottom of the shaft have been attained. The Company's only further regulatory requirement is to alert the local municipal government of its intention to commence this activity, which the Company intends to do in the first week of July.

VanGold Plans Three Initiatives After Clearing Shaft:

Sampling the bottom of the underground stockpile: The underground (UG) stockpile consists of material that in 2012 the Mexican Geological Survey (SGM) agency determined to be 148,966 tonnes in size.[1] In 2017, VanGold conducted a trenching program at the top of the UG stockpile. This program resulted in a weighted average of all of the trench samples of 1.75 gpt Au and 183 gpt Ag, which is similar to the grades quoted in 2012 by SGM of 1.66 gpt Au and 143 gpt Ag.[2] Once crews remove the material at the bottom of the El Pinguico shaft VanGold will be in a position to properly sample the bottom of the UG stockpile and determine whether the silver and gold grades, established by VanGold's trenching in 2017 on the top of the stockpile, extend to the bottom of the stockpile.

2. Inspecting the #7 Sangria Adit: Clearing the El Pinguico shaft will allow crews to enter and inspect the mine's #7 Adit – also known as the "Sangria" adit. This adit may provide a potential safe and inexpensive haulage way to bring the UG stockpile material to surface for onward delivery to a nearby mill for processing. The Company will study this approach for bringing the UG stockpile material out of the mine; however fully refurbishing the El Pinguico shaft is also a potential alternative. The decision on which of these possibilities the Company will pursue will be made once the Sangria adit is entered and fully inspected.

3. Sampling of the Colmillo Stope: Once the El Pinguico shaft has been suitably cleared, it is anticipated that crews will be able to access and sample the Colmillo Stope. This stope was a high grade area within the El Pinguico mine prior to its closure in 1913. Examples of historic sampling from this area, conducted in 1909, can be seen on page 5 of the Company's corporate presentation, available on its Website: www.vangoldmining.com.[3]

Geologist and Vangold Director, Bill Gehlen said "Historical assays from the Colmillo stope area are remarkably high-grade. We want to establish whether that material still exists, whether the grade from our sampling is comparable to historic grades, and whether other areas of high-grade are readily accessible within that part of the old workings. In the months ahead, we plan to test for extensions to these areas with an underground drilling campaign."

The El Pinguico Project:

El Pinguico is a high-grade gold and silver deposit that was mined from the early 1890s until 1913. The mining was done exclusively from the El Pinguico and El Carmen veins, which are thought to be splays off the Mother Vein, or ‘Veta Madre.'

The Veta Madre is associated with a mega fault that outcrops for 25 kilometres and is the most important source of precious metal mineralization in the region. The Veta Madre may cross Vangold's property at depth, underneath the high grade El Pinguico and El Carmen veins. Very limited drilling has been done on the property and no drilling has attempted to encounter the Veta Madre at depth.

Historic stockpiles of mineralized material exist on surface and underground at El Pinguico which may potentially provide feed to one of several operational mills in the Guanajuato area.

Hernan Dorado, a director of Vangold and a qualified person as defined by National Instrument 43-101, Standards of Disclosure for Mineral Projects, has approved the scientific and technical information contained in this news release.

About Vangold Mining Corp.

Vangold Mining is an exploration company engaged in the exploration of mineral projects in the Guanajuato region of central Mexico. The Company's flagship El Pinguico project is a significant past producer of high-grade gold and silver and is located just 7km south of the city of Guanajuato, Mexico. The Company remains focused on the near-term potential for development and monetization of both its surface and underground stockpiles of mineralized material from El Pinguico.

ON BEHALF OF THE BOARD OF DIRECTORS
"James Anderson"
Chairman and CEO

For further information regarding Vangold Mining Corp, please contact:

James Anderson, Director, +1 (778) 989-5346
Email: james@vangoldmining.com
Continue to watch our progress at: www.vangoldmining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains certain forward-looking statements, which relate to future events or future performance (including, but not limited to, the potential for near term development and monetization of existing stockpiles of mineralized material at the Company's El Pinguico project in Mexico) and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, but not limited to, market conditions, availability of financing, currency rate fluctuations, actual results of exploration and development activities, environmental risks, future prices of gold, silver and other metals, operating risks, accidents, labor issues, delays in obtaining governmental or regulatory approvals and permits, and other risks in the mining industry. In addition, there is uncertainty about the spread of the COVID-19 virus and the impact it will have on the Company's operations, global supply chains and economic activity in general. All the forward-looking statements made in this news release are qualified by these cautionary statements and those in our continuous disclosure filings available on SEDAR at www.sedar.com. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required by applicable law.

VANGOLD MINING CORP.
PH: +1(778) 989-5346 E: info@vangoldmining.com W: vangoldmining.com
CA: #1000 – 409 Granville Street, Vancouver, British Columbia V6C 1T2, Canada
MX: Carr, Guanajuato – Silao km 5.5 Colonia Marfil Guanajuato, Mexico Office No.2 CP 36250

[1] This figure is historic in nature, has not been verified and should not be relied upon.

[2] VanGold completed 57 samples from 20 trenches (mostly historic with a few new trenches) at the top of the UG stockpile resulting in the average grades set out above. All samples were collected, recorded, bagged and sent by VanGold's consulting geologist to ALS Laboratory in Guadalajara, Mexico for sample preparation. Gold, silver and multi-element ICP analysis was completed at the ALS laboratory in North Vancouver, Canada. Rock samples were fine crushed (70% passing a 2mm screen), pulverized (85% passing a 75 micron screen) and a pulp split separated for assaying by a riffle splitter. 30 gram portion of each sample was assayed for gold by standard fire assay and a 10 gram split was analyzed for 35 elements by ICP method. Standard reference material and blank samples were inserted into the sample stream at a 5% insertion rate with pulped samples from the UG stockpile for quality control purposes. The results of the standards and blank samples were satisfactory. All data was collected with industry standard practices and assay results were verified by VanGold's consulting geologist. Further work by VanGold is required to verify the tonnage estimation by the Mexican Geological Survey agency and assess the distribution of grades within the UG stockpile.

[3] Historical assays have not been verified and should not be relied upon. They are presented as an indication of possible gold and silver mineralization within the Colmillo stope of the UG stockpile and as a guide for future work.

SOURCE: Vangold Mining Corp.

ReleaseID: 595040

Achieving success in life can be a long and arduous process. Anmol Singh, a trading consultant, knows all about success, and he knows that there are several ways to achieve it

NEW YORK, NY / ACCESSWIRE / June 24, 2020 / Anmol Singh started trading during his early college without much luck. After a year or so of exploring the trading industry, he discovered a pattern that allowed him to go from 0 to a profitable trader. And since then, he has made his name as a high-paid consultant in the trading and investing industry.

Anmol launched Live Traders in 2015, and now, it has been voted as the number 1 trading education firm for three years in a row. Since the company entered the industry, Anmol has coached and trained over a thousand traders and investors. Some of the people he coached and trained have now gone on to run their own hedge funds. Currently, he spends his day working with students of his trading firm, Live Traders, and continues to back them financially. He also remains an avid stock market and forex trader, as well as being involved with other entrepreneurial ventures and franchise stores in the automotive sector.

Anmol is also considered the leading expert in the trading psychology space. This is because he has helped thousands of traders all over the world deal with psychological and behavioral issues that arise when high stakes are on the line.

He is also the author of the best-selling book Prepping for Success: 10 Keys for Making It in Life. Prepping for Success is a guided journey in book form. Anmol wants to impart his unique view on success and shows how the concepts he has used to help million-dollar traders are applicable to day-to-day lives, regardless of the industry or career. In this book, he teaches the principles people need to take advantage of innate, inner talents to achieve success.

Prepping for Success discusses ten keys that allow people to understand themselves and also teach them to become the best version of themselves. The book offers concrete ways to make plans into action, and it gives a relatable step-by-step approach to achieving personal success.

Anmol has said, "With this book, I hope to bring to the readers the main key concept that has helped me in my life and have made me a better and a more productive person, as I, too, prepare for success. I am writing a book that I wish someone gave me ten years ago. It would have made life so much easier."

Anmol Singh is interested in results, which is why he established Live Traders and wrote his book. Anmol believes that anything is possible as long as the person has the knowledge to succeed. At Live Traders, he gives traders the education they need to understand the trade and make logical and fast decisions based on constantly changing data. And with his book, he equips readers with everything they need to know to excel in life.

For more information on Live Traders, visit the website. To get a direct conversation with the man himself, contact Anmol Singh through his number (+1) 929-3031286, or send an email to anmol@livetraders.com.

SOURCE: Authority Titans

ReleaseID: 595049

MIAMI, FL / ACCESSWIRE / June 24, 2020 / Blaux Personal AC is the device recently launched and many Americans are raving about this summer. As the northern hemisphere approaches the height of summer, consumers everywhere are looking for ways to dial down the heat.

The poolside BBQs, family cookouts in the backyard, and long afternoons lazing in the sun aren't quite what they're cracked up to be once the mercury hits those high digits.

Now, Americans are stuck between a rock and a hard place. It's too hot not to blast the AC, but it's too expensive to run the AC when half the house is empty. Ceiling fans, handheld fans, Personal fans, hats with built-in fans… none of these options are effective at really lowering the temperature on a blazing summer day. What's left?

According to the Blaux Personal AC reviews currently trending across the internet, this ultra-portable Blaux Personal air cooler is the answer.

Read the Specifications of Blaux Personal AC at their Official Site Here.

What is Blaux Personal AC?

Blaux Personal AC is a patented, personal air conditioning unit that consumers can actually wear. This nifty device sits around the shoulders to keep its wearer cool, calm, and collected on even the most extreme of summer days.

This high tech personal air cooler also acts as an air purifier, odor eliminator, and humidifier. The Blaux Personal AC is an effective way to reduce sniffles and allergy symptoms as it cools the body.

The lightweight, ultra-comfortable design makes it easy to wear the Blaux Personal personal cooler for hours at a time, without wasting energy on cooling the parts of the home or office that sit empty for hours or days.

Despite its diminutive stature, the Personal personal cooling system is extremely powerful. It is recommended to set the Personal device to low for gentle cooling and air purification as consumers work, nap, or play.

For wearers doing physical work, travelling in hot, enclosed spaces, or when the temperature goes through the roof, the company recommends dialing up the device.

There's no need to worry about the Personal Blaux AC causing any distractions either. The whisper-quiet unit is non-intrusive and will not interfere with mobile devices or electronics.

The engineering team at Blaux truly thought of all possible scenarios when it comes to this lightweight personal cooling system. It purifies the air as it cools, allows ultimate movement and versatility of use, and runs off fast-charge rechargeable batteries through a type-C charger cable that is included in the package. Those who are in disbelief of the capabilities of this device think this is a Blaux Personal scam, which will be addressed later.

Avoid getting counterfeit versions of Blaux, this is the official website: Blaux Portable AC.

How Does Blaux Personal AC work?

Blaux Personal AC has a patented, ultra-compact filtration system.

The unit can be recharged via the type-C charging cable included with every purchase. Once charged, the unit can be turned on and set to the user's desired setting. Thermal cooling plates circulate cool air from the shoulder-facing vents and the cooling vents located at the back of the neck.

The vents can be adjusted to suit individual user preference, making this a highly customizable personal cooling system.

As it cools, ionizer hardware within the fan chamber activates to reduce allergens and pollutants, quietly filtering out harmful toxins.

The Personal Blaux AC runs comfortably and quietly for hours before it needs to be recharged. That's long enough to go for a run, get a full day's work done, or simply sit outside and enjoy the sun without stifling heat and sweaty discomfort.

Savvy consumers are getting the benefit of carrying a clean environment with them, wherever they go.

Can Blaux Personal AC work in all rooms?

100%. Because this Personal AC is worn around the user's shoulders, it can go almost anywhere they do. Perfect for the home and office, the workshop or garage, this versatile personal air conditioning unit is an all-rounder.

Countless Blaux Personal AC reviews are singing praises of the unit for outdoor use as well. According to Blaux customer reviews, this device is suitable for use while running outdoors, playing light sports, and sunbathing at the beach.

But where is this best suitable for? Get details here.

Blaux Personal AC, the Good and The Bad

The Good

Lightweight and Personal

Easy to use

Energy efficient-lasts up to 30 hours on a full charge

Rechargeable and cordless

Powerful air circulation

Removes harmful toxins and allergens as it cools

Versatile cooling with 3 variating fan speeds

Adjustable positioning of front vents

LED to give you a quick glance update on the power level

30 day money back guarantee.

Reliable, stress-free delivery. Blaux ships fast for customer peace of mind.

The Bad

Not waterproof

Cannot be used overnight

Pricey if not purchased with a special deal

To help customers obtain their Blaux Personal AC, the company is offering a special price reduction on each pack option:

Four Blaux Personal AC – The Family Protection Pack = $137.47 (discount pricing from $307.63)

Three Blaux Personal AC – Pure Air Pack = $112.48 (discount pricing from $230.72)

Two Blaux Personal AC – Double Relief Pack = $99.98 (discount pricing from $153.82)

One Blaux Personal AC – Clean Comfort Pack = $49.99 (discount pricing from $76.91)

Blaux Personal AC Reviews: What to expect?

This tiny and easily personal yet incredibly powerful system makes major promises to not only cool air, but also purify it from harmful toxins. This is why Americans are faced with a difficult dilemma: Is this a Blaux Personal AC sham?

The answer is: No. The Blaux Personal AC was simply created by a genius engineering team that has been successful in creating this impressive device.

Reviews for this Personal AC unit are consistent across the internet: The Blaux AC delivers on its promise.

"Blaux lets me set my own cool personal temperature. I like it cool, so I can think clearly and work hard. Having fresh air is also a serious plus. I thought there would be an annoying noise that would keep me from working, yet I bought it anyway. I'm pleasantly surprised to say that it doesn't produce any loud sounds " -Bryce Q.

"I feel a lot better knowing that the air I'm breathing is filtered and safe. The only downside is that I can't take it swimming with me. Really considering getting another one for my wife as well." Carl M.

Technical Specifications

– USB type-C charging cable included

– Air volume guaranteed over 1.8 CFM +

– Adjustable air flow

– Adjustable sizing

– 3 fan speeds

– LED light to indicate power status

– Easy clean-easy care

– 30+ hour run time

– Built-in antibacterial, allergen, and pollutant filter

With a 100% money back guarantee and glowing reviews, it is difficult not to try the Blaux Personal cooler. Its ultra-powerful antibacterial filter and advanced cooling technology are ideal for both indoor and outdoor use, and it seems that there is no other personal cooling system on the market that can give the Blaux a run for its money. Users everywhere are uncovering the internet's secret to a no-sweat summer with the Official Blaux Personal AC.

Contact Blaux

By Email: support@buyblaux.com
By Phone:
Northern America (toll free): 844 846 5344
United Kingdom & Ireland: 03308 082207
Australia & New Zealand: (08) 7282 2012
COMPANY ADDRESS:
Strong Current Enterprises Limited 68308, G/F Kowloon East Building, 12 Lei Yue Mun Road, Kwung Tong, Hong Kong

SOURCE: Blaux Portable AC

ReleaseID: 595048

NEW YORK, NY / ACCESSWIRE / June 24, 2020 / Extended Reality (XR) is a term for the use of computer technology and wearable devices to produce a combination of real and virtual, human-computer interactive environment. The expansion includes augmented reality (AR), virtual reality (VR), mixed reality (MR) and many other forms. In other words, to avoid confusion, XR is a generic term that includes VR, AR, and MR. The XR points are divided into multiple levels, from a virtual world with wired sensor input, to a full virtual world.

Features of 5G, such as high transmission and low delay, can enrich XR application scenarios. The large bandwidth characteristic of 5G network can meet the development demand of XR. 5G overlay edge computing brings low latency and transfers the computing power needed for local rendering to the cloud.

WIMI, as an ecological service provider for 5G applications, focuses on computer vision holographic cloud services. WIMI's product layout business application scenarios are mainly concentrated in five professional fields, including home entertainment, lightfield cinema, performing arts system, commercial publishing system and advertising display system. Based on the imaging detection and recognition technology, template matching and detection technology, video processing and recognition technology, holographic 3D layer replacement technology in imaging recognition and dynamic fusion processing technology in imaging tracking, WIMI embed holographic AR advertisements into online videos. It is hoped that these technologies will be applied to the company's future strategic blueprint, such as the development and application of holographic 3D face recognition technology and holographic face change technology.

The integrated holographic application platform independently developed by WIMI R&D team includes holographic audio-visual integrated operation, holographic advertising service, holographic media asset management and platform-level holographic data management and holographic interaction system, holographic recognition system, holographic label system, holographic tracking system, holographic capture system and holographic analysis system.

According to the prospectus, with the changes in 5G holographic communication network bandwidth conditions, 5G holographic application market will see an explosion, with high-end applications such as holographic interactive entertainment, holographic conference and holographic conference gradually spreading to holographic social networking, holographic communication, holographic navigation and holographic family applications. WIMI plans to use holographic AI face recognition technology and holographic AI face changing technology as the core technologies to support holographic cloud platform services and 5G communication holographic applications with multiple innovative systems.

WIMI's technology platform is built on a highly scalable and flexible cloud-based infrastructure that enables Weimy Hologram to store and leverage the vast amount of real-time data collected from WIMI products and third-party sources, and ensure its high-speed performance in accommodating more business partners. WIMI USES complex data for mining and data analysis based on user behavior to create interest profiles for end users. WIMI collected and analyzed user data from about 350 million reliable end users through WIMI's holographic AR advertising service, resulting in more than 2,000 user tags.

Holographic cloud business will combine with the depth of 5G, 5G in collaboration of high rate and low latency, remote communication and data transmission, from terminal to business server system transmission delay will average about 6 ms, well below the 4 g network transmission delay, ensure the holographic AR in the remote communication and data transmission without caton, low latency, and terminal collaboration in more, when the richness and diversity of interaction. Make the end + cloud collaboration collaboration more efficient. Enhanced mobile broadband (eMBB) and the Internet of things (IoT) application, makes WIMI holographic holographic AR AR advertising business, and entertainment business, as well as the holographic interactive entertainment, holographic meeting, holographic social, holographic communication, holographic family holographic, etc., will be based on facial recognition technology and holographic 5G + AI AI face in face of technology of the core technology for effective growth.

The 2020 Computer Vision and Pattern Recognition Conference brings together computer vision researchers and engineers from around the world, and FB Reality Labs is clearly not missing out on such an event. Chief scientist Michael Abelash gave a video briefing on the team's research and its progress.

Abel rush first reference jobs in Stanford university graduates in 2005 speech for PC graphics interface for the future development direction of quotes (You couldn't it about the inevitability, it was so obvious), points out that as the first wave of HCI revolution began in the 1990 s, the second wave of HCI based on virtual reality and augmented reality revolution also inevitable.

The first WAVE of the HCI revolution was the TWO-DIMENSIONAL computer represented by the PC and smartphone, which brought about a digital world that changed the way we play, work and socialize. But even so, our interactions with the digital world are limited to two-dimensional screens. Instead, Abelash says, virtual and augmented reality holds the promise of harnessing the full power of humans so that digital and reality merge seamlessly.

Abelash believes that future VR headsets will be able to achieve a 200-degree field of view with retina resolution, variable focal length and realistic audio, while AR glasses are super fashionable and could completely replace smartphones and give wearers supersensory abilities. However, the technology required for this vision is far from what it should be, including optical systems, interfaces, touch, avatars and ergonomics.

The first is the optimized hand tracking function. As you can see in the video above, the system can now track rapid hand and finger movements with considerable precision. In this regard, he says, optical hand and finger tracking will become an important component of the space computer paradigm.

FB has also made advances in avatar rendering, including human simulation, bone tracking, motion capture, and Codec Avatars. According to Abelash, it could be a few years before virtual reality renders the digital equivalent of reality.

Augmented reality (AR), it is a technology that calculates the position and Angle of the camera image in real time and adds corresponding images, videos and 3D models. The goal of this technology is to embed the virtual world on the screen and interact with the real world. As the CPU computing power of portable electronics increases, augmented reality will be used more and more.

At present, China's 5G process has been developing in an orderly way. The country has introduced a number of policies to support the construction of 5G network, and the whole 5G ecology has shown a prosperous side. 5G's innovation lies in its network slicing technology, while its advantages lie in its high bandwidth and low latency. For 5G to develop, the current foreseeable application is XR, and the demand for 5G of other traditional services is not rigid. The XR must be developed with high bandwidth and low latency, so 5G will naturally help XR. With 5G support, the application of XR in B terminal will develop rapidly, especially in intelligent manufacturing, smart mines, smart energy, smart medical treatment and smart city. With the promotion of national 5G policies, XR will finally embrace a breakthrough in development. As 5G and XR technologies penetrate into the work flows of enterprises and institutions at all levels, XR in 5G era is bound to be a trillion market.

In recent years, the market for facial recognition applications has been expanding. In order to obtain better accuracy and quality, the application of facial recognition shows a trend of transition from two-dimensional technology to three-dimensional technology. So the reason for this trend is that 2d facial recognition technology is susceptible to gesture, light, appearance and other factors, which can reduce recognition rates. WIMI therefore believes that 3D will gradually replace 3D facial recognition. WIMI Hologram's plan is to provide holographic cloud application services for 3D facial recognition through artificial intelligence-based algorithms. WIMI's future plans are to use WIMI's 3D facial recognition holographic cloud technology to meet potential customers in various industries, such as home, retail, travel, telecommunications, finance, national security, robotics, education, social media, terminal devices, commerce, transportation, intelligent commerce or other potential applications.

Media Contact:

Company: WIMI
Name: Tim Wong
Tele: +86 10 89913328
Email: bjoverseasnews@gmail.com

SOURCE: WIMI

ReleaseID: 595047

Conducted by Jaguar Health subsidiary Napo Pharmaceuticals in collaboration with Puma Biotechnology, the study provides scientific rationale for the use of crofelemer in treating cancer patients receiving targeted therapy agents such as tyrosine kinase inhibitors

SAN FRANCISCO, CA / ACCESSWIRE / June 23, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that a preclinical study evaluating the effects of crofelemer (Mytesi®) in providing symptomatic relief of diarrhea associated with the irreversible pan-HER tyrosine kinase inhibitor (TKI) neratinib (Nerlynx®) is being presented as an e-poster at the American Association for Cancer Research Virtual Annual Meeting II, which takes place June 22 – 24, 2020. The study was conducted by Jaguar subsidiary Napo Pharmaceuticals, Inc. ("Napo") in collaboration with Puma Biotechnology, Inc.

Mytesi, a novel non-opiate chloride ion channel modulator antidiarrheal drug, is currently indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Nerlynx, a drug product of Puma Biotechnology, Inc., is a pan HER TKI indicated for the extended adjuvant treatment of adult patients with early stage HER2 positive breast cancer and also for metastatic HER2 positive breast cancer.

This study provides scientific rationale for the use of crofelemer in providing symptomatic relief of watery diarrhea in patients receiving a targeted cancer therapy drug like neratinib with or without cycle chemotherapy in future clinical studies.

"This 28-day preclinical pharmacological study in healthy female dogs was designed to evaluate the scientific rationale for the use of crofelemer in reducing the severity and incidence of diarrhea associated with a tyrosine kinase inhibitor (neratinib)," said Dr. Michael Guy, DVM, Ph.D., Jaguar's vice president of preclinical and nonclinical studies. "The study was conducted without the prophylaxis or concomitant use of loperamide and demonstrated that crofelemer caused an approximate 30% reduction in the incidence and severity of diarrhea associated with daily oral administration of neratinib, which was statistically significant. Crofelemer also demonstrated significant improvement in the proportion of responder dogs, and there was a trend for fewer neratinib dose reductions in both crofelemer treatment groups when compared to the control group."

"Crofelemer is undergoing development for a potential additional indication of symptomatic relief of cancer therapy-related diarrhea (CTD)," Lisa Conte, Jaguar's president and CEO, stated. We are very excited about these preclinical results and are planning a pivotal trial in CTD patients to evaluate the effects of crofelemer in prevention and/or relief of CTD. Many patients on TKIs require drug holidays or dose reductions in their therapy due to diarrhea. Reduced frequency and severity of diarrhea will allow better maintenance to the therapeutic dose and dosing of any targeted therapies, potentially leading to better clinical outcomes. As we've learned from business development discussions with cancer agent manufacturers, adoption and continued use of TKIs and other targeted cancer therapies is directly related to the ability of patients to tolerate use of the therapies – highlighting the importance of supportive care to help manage treatment-related diarrhea in this patient population."

Dogs in all treatment groups received oral neratinib in the form of one 40 milligram tablet of neratinib for the first five days, which was then escalated from day six onwards to two tablets of neratinib, or 80 milligrams of neratinib once daily for the remainder of the study. Concomitant with the daily neratinib dosing, dogs in the three treatment groups received either placebo capsules or crofelemer (Mytesi) tablets twice a day (BID) or four times a day (QID).

Dogs with mild or moderate dehydration were given fluids as needed and/or a drug holiday of neratinib for reduction of severe diarrhea. No dogs in any treatment group during the study received loperamide to reduce the incidence or severity of diarrhea.

Three of the eight dogs in the control group were found to be "clinical responders" defined as dogs having <7 watery stools per week for 50% of the 28-day dosing period. In contrast, seven of eight dogs treated with oral neratinib and crofelemer QID were responders (p = 0.02), and six of eight dogs treated with oral neratinib and crofelemer BID were responders (p = 0.03), both of which were significantly higher than the control group.

Compared to placebo-treated dogs, the average number of watery stools per week was significantly less for both the crofelemer QID and crofelemer BID treatment groups during Week 1 as well as throughout the entire four-week treatment period.

Over the entire 28-day treatment period, dogs receiving placebo had an approximately 33% higher average number of watery stools when compared to dogs randomized to the crofelemer BID or QID groups (p < 0.05).

Stool consistency, as measured by the average fecal scores per week, demonstrated that dogs in the crofelemer QID treatment group (p = 0.010) and in the crofelemer BID treatment group (p = 0.033) had significantly more formed stools compared to the control group dogs.

When compared to placebo-treated dogs, there was a significant reduction in the average number of watery stools per neratinib tablet for both crofelemer treatment groups during Week 1 as well as over the entire 28-day treatment period.

Finally, stool consistency as measured by the average fecal scores per week per neratinib tablet showed significantly more formed stools for the crofelemer QID and BID groups over the entire 28-day treatment period compared to the control group.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived gastrointestinal products on a global basis. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the development of crofelemer for the potential additional indication of symptomatic relief of CTD, and the expectation that reduced frequency and severity of diarrhea will allow better maintenance to the therapeutic dose and dosing of any targeted therapies in cancer patients, potentially leading to better clinical outcomes. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

ReleaseID: 594549

Conducted by Jaguar Health subsidiary Napo Pharmaceuticals in collaboration with Puma Biotechnology, the study provides scientific rationale for the use of crofelemer in treating cancer patients receiving targeted therapy agents such as tyrosine kinase inhibitors

SAN FRANCISCO, CA / ACCESSWIRE / June 23, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that a preclinical study evaluating the effects of crofelemer (Mytesi®) in providing symptomatic relief of diarrhea associated with the irreversible pan-HER tyrosine kinase inhibitor (TKI) neratinib (Nerlynx®) is being presented as an e-poster at the American Association for Cancer Research Virtual Annual Meeting II, which takes place June 22 – 24, 2020. The study was conducted by Jaguar subsidiary Napo Pharmaceuticals, Inc. ("Napo") in collaboration with Puma Biotechnology, Inc.

Mytesi, a novel non-opiate chloride ion channel modulator antidiarrheal drug, is currently indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Nerlynx, a drug product of Puma Biotechnology, Inc., is a pan HER TKI indicated for the extended adjuvant treatment of adult patients with early stage HER2 positive breast cancer and also for metastatic HER2 positive breast cancer.

This study provides scientific rationale for the use of crofelemer in providing symptomatic relief of watery diarrhea in patients receiving a targeted cancer therapy drug like neratinib with or without cycle chemotherapy in future clinical studies.

"This 28-day preclinical pharmacological study in healthy female dogs was designed to evaluate the scientific rationale for the use of crofelemer in reducing the severity and incidence of diarrhea associated with a tyrosine kinase inhibitor (neratinib)," said Dr. Michael Guy, DVM, Ph.D., Jaguar's vice president of preclinical and nonclinical studies. "The study was conducted without the prophylaxis or concomitant use of loperamide and demonstrated that crofelemer caused an approximate 30% reduction in the incidence and severity of diarrhea associated with daily oral administration of neratinib, which was statistically significant. Crofelemer also demonstrated significant improvement in the proportion of responder dogs, and there was a trend for fewer neratinib dose reductions in both crofelemer treatment groups when compared to the control group."

"Crofelemer is undergoing development for a potential additional indication of symptomatic relief of cancer therapy-related diarrhea (CTD)," Lisa Conte, Jaguar's president and CEO, stated. We are very excited about these preclinical results and are planning a pivotal trial in CTD patients to evaluate the effects of crofelemer in prevention and/or relief of CTD. Many patients on TKIs require drug holidays or dose reductions in their therapy due to diarrhea. Reduced frequency and severity of diarrhea will allow better maintenance to the therapeutic dose and dosing of any targeted therapies, potentially leading to better clinical outcomes. As we've learned from business development discussions with cancer agent manufacturers, adoption and continued use of TKIs and other targeted cancer therapies is directly related to the ability of patients to tolerate use of the therapies – highlighting the importance of supportive care to help manage treatment-related diarrhea in this patient population."

Dogs in all treatment groups received oral neratinib in the form of one 40 milligram tablet of neratinib for the first five days, which was then escalated from day six onwards to two tablets of neratinib, or 80 milligrams of neratinib once daily for the remainder of the study. Concomitant with the daily neratinib dosing, dogs in the three treatment groups received either placebo capsules or crofelemer (Mytesi) tablets twice a day (BID) or four times a day (QID).

Dogs with mild or moderate dehydration were given fluids as needed and/or a drug holiday of neratinib for reduction of severe diarrhea. No dogs in any treatment group during the study received loperamide to reduce the incidence or severity of diarrhea.

Three of the eight dogs in the control group were found to be "clinical responders" defined as dogs having <7 watery stools per week for 50% of the 28-day dosing period. In contrast, seven of eight dogs treated with oral neratinib and crofelemer QID were responders (p = 0.02), and six of eight dogs treated with oral neratinib and crofelemer BID were responders (p = 0.03), both of which were significantly higher than the control group.

Compared to placebo-treated dogs, the average number of watery stools per week was significantly less for both the crofelemer QID and crofelemer BID treatment groups during Week 1 as well as throughout the entire four-week treatment period.

Over the entire 28-day treatment period, dogs receiving placebo had an approximately 33% higher average number of watery stools when compared to dogs randomized to the crofelemer BID or QID groups (p < 0.05).

Stool consistency, as measured by the average fecal scores per week, demonstrated that dogs in the crofelemer QID treatment group (p = 0.010) and in the crofelemer BID treatment group (p = 0.033) had significantly more formed stools compared to the control group dogs.

When compared to placebo-treated dogs, there was a significant reduction in the average number of watery stools per neratinib tablet for both crofelemer treatment groups during Week 1 as well as over the entire 28-day treatment period.

Finally, stool consistency as measured by the average fecal scores per week per neratinib tablet showed significantly more formed stools for the crofelemer QID and BID groups over the entire 28-day treatment period compared to the control group.

About Jaguar Health, Inc.

Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived gastrointestinal products on a global basis. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

For more information about Jaguar, please visit https://jaguar.health. For more information about Napo, visit www.napopharma.com.

About Mytesi®

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding the development of crofelemer for the potential additional indication of symptomatic relief of CTD, and the expectation that reduced frequency and severity of diarrhea will allow better maintenance to the therapeutic dose and dosing of any targeted therapies in cancer patients, potentially leading to better clinical outcomes. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:

Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

ReleaseID: 594549